Merck (MRK) Interest Coverage Ratio (2009 - 2026)
Merck (MRK) posted quarterly Interest Coverage Ratio of 16.14 for Q1 2026, down 303.32% year-over-year from 7.94 in Q1 2025, and down 211.2% quarter-over-quarter from 5.18 in Q4 2025.
Merck (MRK) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Interest Coverage Ratio for 18 consecutive years, with 16.14 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 303.32% year-over-year to 16.14; the TTM figure through Mar 2026 stood at 3.63 (down 193.35% YoY), while the FY2025 annual figure was 3.45, down 5.37% from the prior year.
- Interest Coverage Ratio fell to 16.14 in Q1 2026 per MRK's latest filing, from 5.18 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 8.84 in Q3 2025 and bottomed at 33.79 in Q2 2023.
- Historically, Interest Coverage Ratio has averaged 2.26 across 5 years, with a median of 0.03 in 2024.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio tumbled 3092.21% — and 2025, when it jumped 29065.14%.
- Merck's Interest Coverage Ratio stood at 1.57 in 2022, then slumped by 1127.32% to 19.22 in 2023, then soared by 104.98% to 0.96 in 2024, then plunged by 641.23% to 5.18 in 2025, then tumbled by 211.2% to 16.14 in 2026.
- Business Quant data shows MRK's Interest Coverage Ratio at 16.14 in Q1 2026, 5.18 in Q4 2025, and 8.84 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.04 Bn | 633.28 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 470.61 Bn | 464.04 Bn | 12.70 Bn | - |
| 3 | Merck | 379.00 Bn | 371.86 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.30 Bn | 295.61 Bn | 11.24 Bn | 10.28 |
| 5 | Astrazeneca | 258.47 Bn | 253.57 Bn | 12.86 Bn | 7.27 |
| 6 | Amgen | 237.78 Bn | 223.79 Bn | 7.24 Bn | 5.22 |
| 7 | Gilead Sciences | 183.75 Bn | 180.57 Bn | 6.22 Bn | -42.08 |
| 8 | Pfizer | 160.91 Bn | 149.21 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.07 Bn | 101.90 Bn | 8.24 Bn | -2.64 |
| 10 | Sanofi | 55.31 Bn | 47.93 Bn | 10.79 Bn | -50.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.67 |
| Mar 31, 2026 | -16.14 |
| Dec 31, 2025 | -5.18 |
| Sep 30, 2025 | 8.84 |
| Jun 30, 2025 | 4.73 |
| Mar 31, 2025 | 7.94 |
| Dec 31, 2024 | 0.96 |
| Sep 30, 2024 | 0.03 |
| Jun 30, 2024 | 7.29 |
| Mar 31, 2024 | 7.03 |
| Dec 31, 2023 | -19.22 |
| Sep 30, 2023 | 4.28 |
| Jun 30, 2023 | -33.79 |
| Mar 31, 2023 | -1.14 |
| Dec 31, 2022 | -1.57 |
| Sep 30, 2022 | -1.44 |
| Jun 30, 2022 | 1.13 |
| Mar 31, 2022 | -2.14 |
| Dec 31, 2021 | 0.17 |
| Sep 30, 2021 | 9.27 |